Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.3.4.6 (urease)
 7,490 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Several reports, conducted as a placebo-controlled, double-blind study, presented a favorable result in treating MHE. They included branched chain aminoacid, fluzazenil-a benzodiazepin receptor antagonist, lactulose, lactitol, and L-ornithin-L-aspartate. Lactulose and lactitol have been shown to be effective in MHE. It improved psychomotor tests and lowered ammonia levels as well as quality of life. Branched chain amino acids (BCAAs) were reported to improve nitrogen metabolism, blood ammonia level, and psychomotor tests. Flumazenil, an antagonist of benzodiazepine receptor, has not been associated with established consensus on the effectiveness in MHE. L-ornithine-L-aspartate (OA) exerts its ammonia-lowering action in the kidney, skeletal muscles, brain, as well as in the liver. OA administered per orally improved number connection test, ammonia levels, and mental state. OA may be a promising therapy for patients with MHE. A shunt-closure manipulation with balloon occluded retrograde transvenous obliteration (BRTO) has been shown to be effective for hepatic encephalopathy and its efficacy in MHE has not been elucidated. Synbiotic modulation of gut flora. was shown to increase fecal content of non-urease-producing Lactobacillus species and this change was associated with a reversal of MHE. In conclusion, there are no definitive conclusion on the treatment of MHE because of difficulties in diagnosis and evaluation. Therapeutic strategy should be planned specifically for each patient depending on the etiological factors.
 ...
PMID:Treatment of minimal hepatic encephalopathy. 1912 44

The effects of lactulose on the release of ammonia and medium-molecular-weight substances from the intestine into the blood and on the severity of cyclophosphamide intoxication were studied in rats. The pH and urease-dependent component of ammonia-producing activity of the cecal chyme decreased over 6 h after lactulose administration, while ammonia content in the chyme increased. Cyclophosphamide caused an increase in ammonia and, less so, glutamine level in the portal blood and in the blood collected after decapitation; this drug stimulated release of methylene blue and endogenous substances of medium-molecular-weight to the portal blood. Lactulose was virtually inessential for these changes and for the neurological status, mortality, and medium life span of rats. Hence, lactulose did not prevent cyclophosphamide-induced leakage of ammonia and medium-molecular-weight substances from the gastrointestinal tract into blood and did not reduce the severity of intoxication.
 ...
PMID:Effects of cyclophosphamide and lactulose on the release of ammonia and medium-molecular-weight substances from the intestine into blood in rats. 2348 81

Gut-produced ammonia plays a vital role in the pathogenesis of hepatic encephalopathy because cirrhotic liver fails to clear toxic metabolites. Small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhosis add to the pathogenesis. Lactulose is a mainstay in the treatment of hepatic encephalopathy. Another benefit of lactulose is its prebiotic effect on probiotics that reduce the activity of bacterial urease, resulting in decreased hyperammoneamia and increased elimination of ammonia and other nitrogenous waste through enteric toxin reduction technology. Synbiotic formulation of probiotic and lactulose can synergistically/additively reduce ammonia production, increase utilization and excretion of ammonia and other nitrogenous wastes, thereby improving the well-being of patients with hepatic encephalopathy. We hypothesize that oral administration of a synbiotic formulation prepared from a combination of selected microbial strains of probiotics and lactulose will offer additional protection against hepatic encephalopathy via intra-intestinal extraction of toxic solutes in patients with cirrhosis.
...
PMID:Synbiotic formulation of probiotic and lactulose combination for hepatic encephalopathy treatment: a realistic hope? 2375 57